

Express Mail Label No.: ET176335165US

Date of Deposit: April 4, 2002



Attorney Docket No. 24024-501

14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Peled *et al.*

SERIAL NUMBER: 09/463,320

EXAMINER: D. Saunders

FILING DATE: January 22, 2000

ART UNIT: 1644

FOR: METHODS OF CONTROLLING PROLIFERATION AND
DIFFERENTIATION OF STEM AND PROGENITOR CELLS

April 4, 2002
Boston, MA

Box DAC

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
APR 09 2002
OFFICE OF PETITIONS

PETITION FOR REVIVAL OF AN UNINTENTIONALLY-ABANDONED
PATENT APPLICATION UNDER 37 C.F.R. 1.137(b)

1. This petition is to request revival of the above-referenced application under 37 CFR 1.137(b). In February 2002, Applicant's attorney telephoned the Examiner and was informed that the application had gone abandoned for failure to submit a computer readable form (CRF) of the "SEQUENCE LISTING" in the application. Our records show that such a SEQUENCE LISTING was hand carried to the Examiner in July 2001. The Examiner also communicated at that time that a Notice of Abandonment was being prepared and would be mailed shortly. As of the date of this Petition, a Notice of Abandonment has not yet been received in our office, despite numerous inquiry calls to check on the status of the case. Accordingly, Applicants are filing this petition to revive the application. If the case has not in fact gone abandoned, Applicants request notification of its status.
2. The subject matter of the present application has significant and important implications in the field of medicine and health and Applicant is being unfairly penalized by the delay in prosecution.
3. A paper copy of the "Sequence Listing" was submitted with Applicants' Response dated March 22, 2001. Our records indicate that CRF was also submitted, but the USPTO states that it did not receive a CRF. A CRF was hand carried to the Examiner in July 2000. In addition, a Reply to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated June 20, 2001, is submitted herewith. The Reply includes an initial computer readable form (CRF) copy of the "Sequence Listing", a substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification, and a statement that the content of the paper and computer readable copies are the same and include no new matter as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(c).

04/08/2002 GTEFFERA 00000058 09463320

01 FC:241

640.00 OP

Ref: 07/05/2002
Name: 09463320
FC: 241
-04/08/2002 GTEFFERA-00000058 09463320
-01 FC:241
-640.00 OP

4. The entire delay in filing the required reply from the due date for the reply until the filing of the present petition was unintentional (37 C.F.R. § 1.137(b)(3)).
5. A check (#11733) in the amount of \$640.00 for filing the Petition is enclosed (37 C.F.R. §1.17(m)).
6. The Reply to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures", which includes a computer readable form (CFR) copy of the "Sequence Listing", a substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification, and a statement that the content of the paper and computer readable copies are the same and include no new matter as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d), is enclosed.
7. A return receipt postcard is enclosed.
8. The Commissioner is hereby authorized to charge any additional fees that may be due, or to credit any overpayment of same, to Account 50-0311, Ref. No. 24024-501.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000

Date: April 4, 2002

TRA 1630117v3